7th Cir. Refuses to Reinstate 1,000 Testosterone Replacement Drug Cases, Says Claims Preempted



DOCUMENTS
  • Opinion


CHICAGO - A federal appeals court has refused to reinstate the claims of more than 1,000 plaintiffs against Pfizer Inc. in connection with its Depo-T testosterone replacement drug, finding they are preempted because they would require the drug maker to add additional warnings to its label in contravention of federal law.

In a Jan. 19 opinion, the 7th Circuit U.S. Court of Appeals affirmed that federal law bars reference listed drug (RLD) abbreviated new drug application holders from unilaterally changing their warning labels. The court further held that like all other ANDA holders, Pfizer must match the labeling for the …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Benzene Litigation - Using Genomics in the Courtroom

February 18, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS



HarrisMartin's Webinar Series: New Jersey Asbestos Litigation

February 11, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS